{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
Status:
Possibly Marketed Outside US
Source:
ANDA075357
(2023)
Source URL:
First approved in 2023
Source:
ANDA075357
Source URL:
Class (Stereo):
CHEMICAL (ABSOLUTE)
Status:
Possibly Marketed Outside US
Source:
Anti aging by XIAN CHIANG COMPANY LIMITED
(2023)
Source URL:
First approved in 2023
Source:
Anti aging by XIAN CHIANG COMPANY LIMITED
Source URL:
Class (Stereo):
CHEMICAL (ACHIRAL)
Targets:
Conditions:
Fisetin, a natural flavonoid found in various fruits, vegetables, and nuts, has various biological properties, including anti-inflammatory, anti-oxidant, neuroprotective in cell culture and in animal models relevant to human diseases. Fisetin can be also a promising agent for the treatment of uveal melanoma. Besides, it is a therapeutic agent for respiratory inflammatory diseases such as chronic obstructive pulmonary disease (COPD), where fisetin inhibits the TNF-α-activated IKK/NF-κB cascade by targeting PKCδ. In vitro and in vivo experiments have revealed that fisetin possesses significant therapeutic effects against diabetic complications and atherosclerosis, where it can suppress vascular inflammatory processes.
Status:
Possibly Marketed Outside US
Source:
M020
(2023)
Source URL:
First approved in 2023
Source:
M020
Source URL:
Class (Stereo):
CHEMICAL (MIXED)
Status:
Possibly Marketed Outside US
Source:
21 CFR 358H
(2023)
Source URL:
First approved in 2023
Source:
21 CFR 358H
Source URL:
Class (Stereo):
CHEMICAL (ACHIRAL)
Status:
Possibly Marketed Outside US
Source:
M017
(2023)
Source URL:
First approved in 2023
Source:
M017
Source URL:
Class (Stereo):
CHEMICAL (ACHIRAL)
Status:
Possibly Marketed Outside US
Source:
M017
(2023)
Source URL:
First approved in 2023
Source:
M017
Source URL:
Class (Stereo):
CHEMICAL (ACHIRAL)
Status:
Possibly Marketed Outside US
Source:
21 CFR 333D
(2023)
Source URL:
First approved in 2023
Source:
21 CFR 333D
Source URL:
Class (Stereo):
CHEMICAL (ABSOLUTE)
Status:
Possibly Marketed Outside US
Source:
21 CFR 352
(2023)
Source URL:
First approved in 2023
Source:
21 CFR 352
Source URL:
Class (Stereo):
CHEMICAL (ACHIRAL)
Status:
Possibly Marketed Outside US
Source:
21 CFR 340
(2023)
Source URL:
First approved in 2023
Source:
21 CFR 340
Source URL:
Class (Stereo):
CHEMICAL (EPIMERIC)
Status:
Possibly Marketed Outside US
Source:
DR.K CELL REPAIR GENIC AMPOULE by Noblesse Korea Co., Ltd.
(2023)
Source URL:
First approved in 2023
Source:
DR.K CELL REPAIR GENIC AMPOULE by Noblesse Korea Co., Ltd.
Source URL:
Class (Stereo):
CHEMICAL (ABSOLUTE)